SynthesisPharmacology research & perspectives2021

Daratumumab provides a survival benefit in relapsed and refractory Multiple Myeloma, independent of baseline clinical characteristics: A meta-analysis.

Congcong Cao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.